Liquidia (LQDA) said Friday the US Food and Drug Administration accepted its resubmitted new drug application for Yutrepia inhalation powder to treat pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
The company said the FDA classified the resubmission as a complete, Class 1 response to an August 2024 action letter that granted tentative approval of Yutrepia, or treprostinil.
The agency set a May 24 target action date, Liquidia said.
Shares of the company were up 1.5% in recent trading Friday.
Price: 15.47, Change: +0.23, Percent Change: +1.48
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.